ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer. The company's core business model revolves around the discovery, development, and potential commercialization of product candidates, primarily through a combination of internal research and development and strategic collaborations. Revenue generation is currently absent from product sales, licenses, or collaborations, with funding historically derived from equity offerings and debt financings ¹. The company's primary customer segments, once products are approved, would be patients and healthcare providers in the oncology space.

The company's pipeline includes two clinical-stage product candidates: evorpacept and ALX2004. Evorpacept is a CD47 blocker designed to treat cancer by preventing cancer cells from evading macrophage phagocytosis. It is a fusion protein combining a high-affinity CD47 binding domain with a proprietary inactivated Fc domain, engineered to avoid hematologic toxicities seen with other CD47 blocking approaches ². This design aims for a broader therapeutic window, higher dosing levels, increased tumor penetration, and greater combination potential with other anti-cancer agents ³. Evorpacept is currently being evaluated in the Phase 2 ASPEN-09-Breast clinical trial for metastatic HER2-positive breast cancer in combination with trastuzumab and chemotherapy ⁴. It has also been studied in the ASPEN-06 Phase 2 clinical trial for HER2-positive gastric/gastroesophageal junction (GEJ) cancer, where it demonstrated a 65.0% objective response rate (ORR) versus 26.1% for the control arm in patients with retained HER2-positive and CD47-high gastric cancer (n=43) ⁵. The median duration of response (mDOR) in this subgroup was 25.5 months for Evo-TRP versus 8.4 months for TRP ⁶. Evorpacept is also being explored in collaborations and investigator-sponsored trials (ISTs) in combination with zanidatamab for HER2-expressing breast cancer and other solid tumors, rituximab and lenalidomide for non-Hodgkin lymphoma (NHL), and isatuximab-irfc and dexamethasone for relapsed or refractory multiple myeloma ⁷.

The second product candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate (ADC). ALX2004 was developed in-house and features a matuzumab-derived affinity-selected EGFR antibody backbone, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability ⁸. This design aims to overcome toxicity limitations of earlier-generation EGFR-targeted ADCs ⁹. ALX2004 entered a Phase 1 clinical trial in August 2025 for advanced or metastatic select EGFR-expressing solid tumors, and as of January 2026, had cleared the first two dose cohorts without dose-limiting toxicities ¹⁰.

For the fiscal year ended December 31, 2025, the company reported a net loss of $101.7 million ¹¹, an improvement from a net loss of $134.9 million in 2024 ¹². Total operating expenses decreased by $38.446 million, from $142.467 million in 2024 to $104.021 million in 2025 ¹³. Research and development (R&D) expenses decreased by $39.4 million, from $116.373 million in 2024 to $76.996 million in 2025 ¹⁴. This decrease was primarily due to a $17.5 million reduction in clinical and development costs, a $12.3 million decrease in stock-based compensation, a $6.0 million decrease in personnel and related costs, and a $4.6 million decrease in preclinical costs ¹⁵. General and administrative (G&A) expenses decreased by $2.2 million, from $26.094 million in 2024 to $23.850 million in 2025 ¹⁶. Interest income decreased by $5.4 million to $3.964 million in 2025 from $9.366 million in 2024 ¹⁷, while interest expense decreased by $0.1 million to $1.602 million in 2025 from $1.729 million in 2024 ¹⁸. An impairment charge of $3.175 million was recorded in 2025, with no comparable charge in 2024 ¹⁹. As of December 31, 2025, the company had cash, cash equivalents, and investments of $48.3 million ²⁰ and an accumulated deficit of $722.8 million ²¹.

During the reported period, ALX Oncology streamlined its evorpacept development program in August 2025 to focus resources on the ASPEN-09-Breast trial, pausing the ASPEN-CRC study that had been announced in March 2025 ²². The company also received guidance from the FDA in April 2025 that the ASPEN-06 Phase 2 trial data was not eligible for accelerated approval, necessitating a Phase 3 trial versus ENHERTU for a U.S. registrational path in gastric cancer, which the company will not pursue, instead considering development partnerships ²³. In January 2026, the first patient was dosed in the ASPEN-09-Breast trial ²⁴. For ALX2004, an IND application was filed in March 2025 and cleared by the FDA in April 2025, leading to the dosing of the first patient in a Phase 1 clinical trial in August 2025 ²⁵. By January 2026, the trial had begun enrolling patients in the third dose cohort at 4 mg/kg, having cleared the first two dose cohorts without dose-limiting toxicities ²⁶.

ALX Oncology anticipates continued significant expenses and increasing operating losses for the foreseeable future as it advances its product candidates. The company expects to finance operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements ²⁷. As of December 31, 2025, the company had cash, cash equivalents, and investments of $48.3 million ²⁸. However, with net proceeds of $140.3 million raised from a registered offering that closed in February 2026 ²⁹, the company believes its existing capital resources will be sufficient to fund operations through the first half of 2028 ³⁰.

The primary growth area for ALX Oncology is the advancement of evorpacept as a foundational checkpoint immunotherapy, particularly through combination therapies with anti-cancer antibodies. The company's strategy emphasizes expanding the therapeutic potential of CD47 blockade by combining evorpacept with other anti-cancer antibodies, believing its design overcomes limitations of other CD47 blocking approaches ³¹. The ASPEN-09-Breast trial, evaluating evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer, is a key focus, with the first patient dosed in January 2026 ³². The company also plans to explore development partnerships for evorpacept in gastric cancer, following FDA guidance that a Phase 3 trial versus ENHERTU would be needed for U.S. regulatory approval in the second-line setting, a path the company will not pursue independently ³³.

Another significant growth vector is the development of ALX2004, a novel EGFR-targeted ADC. The company aims to develop a best- and first-in-class EGFR-targeted ADC, leveraging its differentiated design to overcome toxicity challenges that limited earlier-generation EGFR-targeted ADCs ³⁴. ALX2004 entered a Phase 1 clinical trial in August 2025, targeting EGFR-expressing solid tumors, including NSCLC, HNSCC, CRC, and ESCC, which represent a significant unmet need with over 450,000 metastatic patients in the U.S. alone ³⁵. Initial safety data for ALX2004 is anticipated in the first half of 2026 ³⁶.

Operationally, the company anticipates that its general and administrative expenses will decrease as a result of a completed reduction in workforce ³⁷. However, other factors such as inflationary pressures and higher costs for consulting, legal, tax, and regulatory services may affect these expenses ³⁸. The company relies on third-party contract manufacturing organizations (CMOs) for both drug substance and drug product, with existing supplies of evorpacept and ALX2004 sufficient through the first quarter of 2026 ³⁹. Additional supplies are planned with existing CMOs to support ongoing and planned clinical trials ⁴⁰.

Planned capital allocation includes advancing the clinical development of evorpacept and ALX2004, additional preclinical research, hiring additional personnel, capital expenditures, potential acquisitions, and general corporate purposes ⁴¹. The company's Loan Agreement with Oxford Finance LLC, Oxford Finance Credit Fund II LP, and Silicon Valley Bank (now SVB-First Citizens) provides for $25.0 million available for draw down at the lenders' sole discretion as of December 31, 2025 ⁴². The company also has an effective resale shelf registration statement for aggregate offerings of up to $364.1 million of securities, including up to $119.1 million of common stock through an at-the-market (ATM) offering ⁴³.

The company explicitly flags several structural headwinds and execution risks. The FDA's guidance that ASPEN-06 Phase 2 data was not eligible for accelerated approval for gastric cancer, requiring a Phase 3 trial versus ENHERTU, has led the company to not pursue a U.S. registrational path independently for this indication ⁴⁴. The company also acknowledges that the outcome of preclinical testing and early clinical trials may not be predictive of success in later trials, citing the April 2025 announcement that topline data from Phase 2 ASPEN-03 and ASPEN-04 clinical trials did not meet primary endpoints, leading to the discontinuation of evorpacept in combination with pembrolizumab in HNSCC ⁴⁵. The FDA's draft guidance on clinical trial considerations for accelerated approval of oncology therapeutics, favoring randomized controlled trials, could delay clinical timelines, especially for single-arm studies like ASPEN-09-Breast ⁴⁶. Geopolitical risks, such as the ongoing unrest related to Russia's war with Ukraine and instability in Israel, are also noted as potential adverse impacts on business ⁴⁷.

The company faces material risks including significant net losses since inception, with an accumulated deficit of $722.8 million as of December 31, 2025 ⁴⁸, and the need for substantial additional capital to finance operations, which may not be available on acceptable terms ⁴⁹. There is a high dependency on the success of lead product candidates, evorpacept and ALX2004, which are in clinical development and have not completed pivotal trials, with no guarantee of regulatory approval or successful commercialization ⁵⁰. Clinical trials are expensive, time-consuming, and may fail to demonstrate adequate safety, purity, and efficacy, as evidenced by the discontinuation of evorpacept in HNSCC after Phase 2 trials failed to meet primary endpoints ⁵¹. Product candidates may cause significant adverse events or undesirable side effects, which could prevent regulatory approval or limit commercial potential, with common adverse events for evorpacept including fatigue, anemia, nausea, diarrhea, constipation, and neutrophil count decrease ⁵². The regulatory approval processes are lengthy and unpredictable, and even with Fast Track or Orphan Drug designations, approval is not guaranteed, and benefits may be limited or revoked ⁵³. The company relies on third-party manufacturers, increasing the risk of insufficient quantities, unacceptable cost or quality, or delays in development or commercialization ⁵⁴. Intellectual property protection is crucial but uncertain, with risks of challenges to validity, enforceability, or scope of patents, and the potential need for licenses from third parties that may not be available on commercially reasonable terms ⁵⁵. Macroeconomic conditions, including inflation, interest rate changes, and global disputes, along with geopolitical risks such as the war in Ukraine and instability in Israel, could adversely impact business, clinical trials, and preclinical research ⁵⁶.

Management's overall tone emphasizes a disciplined focus on advancing a pipeline of novel therapies to treat cancer, particularly leveraging evorpacept as a foundational checkpoint immunotherapy and developing ALX2004 as a best- and first-in-class EGFR-targeted ADC. They acknowledge the significant financial investment required for drug development and the need for additional capital, stating that existing cash, cash equivalents, and investments, combined with the $140.3 million ⁵⁷ net proceeds from the February 2026 offering, are expected to fund operations through the first half of 2028 ⁵⁸. Strategic priorities include expanding the therapeutic potential of CD47 blockade by combining evorpacept with anti-cancer antibodies, developing ALX2004, and continuing to develop strategic partnerships to broaden the impact of current and future product candidates ⁵⁹. Management has made a strategic decision to not pursue a U.S. registrational path with a Phase 3 trial in gastric cancer for evorpacept, given FDA guidance, and will instead consider exploring development partnerships for this program ⁶⁰. They also highlight the importance of their team of industry veterans in advancing the development plan, with key executives bringing extensive experience in institutional healthcare investment, clinical drug development, and company founding ⁶¹.